Becker Capital Management Inc. Sells 12,756 Shares of Hologic, Inc. $HOLX

Becker Capital Management Inc. decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 15.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,145 shares of the medical equipment provider’s stock after selling 12,756 shares during the period. Becker Capital Management Inc.’s holdings in Hologic were worth $4,440,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Door Asset Management LLC bought a new position in shares of Hologic in the second quarter worth approximately $10,523,000. Harvest Management LLC purchased a new position in Hologic in the 2nd quarter worth approximately $489,000. Lombard Odier Asset Management USA Corp bought a new position in Hologic in the 2nd quarter valued at approximately $336,000. Daiwa Securities Group Inc. boosted its stake in Hologic by 5.5% during the 2nd quarter. Daiwa Securities Group Inc. now owns 33,734 shares of the medical equipment provider’s stock valued at $2,198,000 after purchasing an additional 1,767 shares during the last quarter. Finally, SVB Wealth LLC bought a new stake in shares of Hologic in the 2nd quarter worth $412,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.1%

Shares of Hologic stock opened at $74.83 on Thursday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $77.32. The company’s fifty day simple moving average is $72.74 and its 200-day simple moving average is $68.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The stock has a market capitalization of $16.68 billion, a PE ratio of 30.17, a P/E/G ratio of 2.12 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period last year, the firm earned $1.01 EPS. Hologic’s revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. Argus upped their target price on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Morgan Stanley boosted their price objective on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Finally, Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Five equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $79.29.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.